Clinical Trial Update: MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MRG003 in combination with pucotenlimab for anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Poorly Differentiated Thyroid Carcinoma

Drugs mentioned

• MRG003
• Pucotenlimab

Snippet

Sponsor: Fudan University | Conditions: Thyroid Cancer | Phase 2 | Status: RECRUITING